Aldeyra's eye drug fails pivotal test in patients with rare, inflammatory disease
Months after eye drug developer Aldeyra Therapeutics tasted Phase III success, it has stumbled in another late-stage study with its lead experimental drug.
The eye drops, reproxalap, are designed to work by diminishing aldehyde levels, which can contribute to inflammation. In the Phase III SOLACE trial, the drug met neither the primary endpoint nor secondary goals in patients with noninfectious anterior uveitis — a rare, severe, ocular inflammatory disease that can lead to blindness. The Lexington, Massachusetts-based drug developer did not disclose the numbers.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.